EFFECT OF INFLIXIMAB ON PARAMETERS OF REMODELING OF ARTERIAL BLOODSTREAM, RANKL AND OSTEOPROTEGERIN LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS

EFFECT OF INFLIXIMAB ON PARAMETERS OF REMODELING OF ARTERIAL BLOODSTREAM, RANKL AND OSTEOPROTEGERIN LEVELS IN PATIENTS WITH RHEUMATOID ARTHRITIS

Objective. To study the effect of infliximab (INF) on serum levels of RANKL and osteoprotegerin (OPG), as well as on structural and functional properties of the vascular wall in patients with rheumatoid arthritis (RA).Material and Methods. A total of 79 RA patients who corresponded to the classifica...

Full description

Bibliographic Details
Main Authors:	Larisa Aleksandrovna Knyazeva, N S Meshcherina
Format:	Article
Language:	Russian
Published:	IMA PRESS LLC 2014-02-01
Series:	Научно-практическая ревматология
Subjects:	infliximab rheumatoid arthritis remodeling of cardiovascular bloodstream rankl osteoprotegerin
Online Access:	https://rsp.mediar-press.net/rsp/article/view/1350

Similar Items

Serum sRAGE, sRANKL and osteoprotegerin in subgroups of rheumatoid arthritis patients: biomarkers associated with iron and disease status
by: Ginka Delcheva, et al.
Published: (2023-03-01)

RANK, RANKL and osteoprotegerin in arthritic bone loss
by: M.C. Bezerra, et al.
Published: (2005-02-01)

EFFECT OF GOLIMUMAB ON IMMUNOLOGICAL MARKERS FOR BONE METABOLISM AND ON ARTERIAL STIFFNESS IN PATIENTS WITH RHEUMATOID ARTHRITIS
by: L. A. Knyazeva, et al.
Published: (2018-07-01)

Osteoclast activity in osteoporosis mandibular bone based on RANKL and osteoprotegerin ratio.
by: Mefina Kuntjoro, et al.
Published: (2021-11-01)

The association of osteoprotegerin and RANKL with osteoporosis: a systematic review with meta-analysis
by: Guanghao Chi, et al.
Published: (2023-11-01)

Associations of Bone Mineral Density with RANKL and Osteoprotegerin in Arab Postmenopausal Women: A Cross-Sectional Study
by: Osama E. Amer, et al.
Published: (2022-07-01)

Circulating levels of osteoprotegerin and sRANKL and the effect of methotrexate in patients with rheumatoid arthritis
by: Aadhaar Dhooria, et al.
Published: (2018-01-01)

Guizhi-Shaoyao-Zhimu decoction attenuates bone erosion in rats that have collagen-induced arthritis via modulating NF‐κB signalling to suppress osteoclastogenesis
by: Shu-jun Wei, et al.
Published: (2021-01-01)

Infliximab in the therapy of rheumatoid arthritis
by: G. V. Lukina, et al.
Published: (2016-05-01)

INFLIXIMAB (REMICADE): POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: Nataliya Vladimirovna Chichasova, et al.
Published: (2011-03-01)

INFLIXIMAB (REMICADE): POSSIBILITIES IN THE TREATMENT OF RHEUMATOID ARTHRITIS
by: Nataliya Vladimirovna Chichasova, et al.
Published: (2011-03-01)

STUDY OF SERUM OSTEOPROTEGERIN AND RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA-Β LIGAND IN PATIENTS WITH RHEUMATIC DISEASES
by: Mariela Geneva-Popova, et al.
Published: (2021-12-01)

Bone mineral density in egyptian children with juvenile idiopathic arthritis: possible correlation to serum RANKL / osteoprotegerin (OPG) ratio and OPG gene polymorphisms
by: Riham Eid, et al.
Published: (2023-06-01)

Development of Anti-bodies against Infliximab in Iraqi Patients with Rheumatoid Arthritis.
by: Mohammed A. Al-Karkhi, et al.
Published: (2015-10-01)

EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)
by: E.I. Alexeeva, et al.
Published: (2006-03-01)

EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)EFFICACY OF INFLIXIMAB IN THERAPY OF REFRACTORY JUVENILE RHEUMATOID ARTHRITIS (JRA)
by: E.I. Alexeeva, et al.
Published: (2006-01-01)

Alendronate (ALN) combined with Osteoprotegerin (OPG) significantly improves mechanical properties of long bone than the single use of ALN or OPG in the ovariectomized rats
by: Chan Kai-Ming, et al.
Published: (2011-07-01)

Osteomesopyknosis associated with a novel ALOX5 variant that impacts the RANKL pathway
by: Jose L. Fernandez‐Luna, et al.
Published: (2024-05-01)

Receptor activator of nuclear factor-κB ligand and osteoprotegerin: maintaining the balance to prevent bone loss
by: Anne-Priscille Trouvin, et al.
Published: (2010-11-01)

Osteopontin, osteoprotegerin and musculoskeletal ultrasound findings in first-degree relatives of rheumatoid arthritis: potential markers of preclinical disease
by: Eiman Soliman, et al.
Published: (2024-03-01)

Functionalized calcium phosphate nanoparticles to direct osteoprotegerin to bone lesion sites in a medaka (Oryzias latipes) osteoporosis model
by: Nurgul Imangali, et al.
Published: (2023-02-01)

Clinical experience with infliximab administration in patients with rheumatoid arthritis by Russian register data
by: Galina Viktorovna Lukina, et al.
Published: (2009-08-01)

EFFICACY OF INFLIXIMAB IN RHEUMATOID ARTHRITIS: A RELATIONSHIP TO THE TOTAL DOSE OF THE DRUG
by: E. S. Aronova, et al.
Published: (2015-10-01)

The association of serum RANKL levels with disease activity and hematological parameters in Syrian patients with rheumatoid arthritis
by: Rama Hussein, et al.
Published: (2022-12-01)

Oligomeric proanthocyanidins ameliorates osteoclastogenesis through reducing OPG/RANKL ratio in chicken's embryos
by: Gengsheng Yu, et al.
Published: (2024-06-01)

Prognostic Value of Serum Osteoprotegerin Level in Patients With Hepatocellular Carcinoma Following Surgical Resection
by: Chihao Zhang, et al.
Published: (2021-09-01)

Vertebral marrow fat fraction is associated with circulating RANKL in postmenopausal females
by: Xuefeng Li, et al.
Published: (2024-09-01)

Comparative study of the synovial levels of RANKL and OPG in rheumatoid arthritis, spondyloarthritis and osteoarthritis
by: Thaíse Oliveira Quaresma, et al.
Published: (2023-03-01)

Serum OPG and RANKL Levels as Risk Factors for the Development of Cardiovascular Calcifications in End-Stage Renal Disease Patients in Hemodialysis
by: Michalis Spartalis, et al.
Published: (2023-02-01)

Gestational protein restriction alters the RANKL/OPG system in the dental germ of offsprings
by: Bruno Calsa, et al.
Published: (2020-10-01)

THE ROLE OF OSTEOPROTEGERIN SYSTEM /RANKL/RANK IN PATHOGENESIS OF AORTIC STENOSIS
by: O. B. Irtyuga, et al.
Published: (2018-03-01)

Duchenne muscular dystrophy: RANK/RANKL/OPG (receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin) system and glucocorticoids
by: Salvador Atilano-Miguel, et al.
Published: (2022-01-01)

Supranutritional selenium suppresses ROS‐induced generation of RANKL‐expressing osteoclastogenic CD4+ T cells and ameliorates rheumatoid arthritis
by: Jiahuan Qin, et al.
Published: (2021-01-01)

Comparative clinical efficacy and safety of the proposed biosimilar ABP 710 with infliximab reference product in patients with rheumatoid arthritis
by: Mark C. Genovese, et al.
Published: (2020-03-01)

INFLIXIMAB-INDUCED LUPUS-LIKE SYNDROME IN A FEMALE PATIENT WITH RHEUMATOID ARTHRITIS (A CASE REPORT): AN ACCIDENT OR REGULARITY?
by: Yu. V. Muravyev, et al.
Published: (2017-09-01)

Diagnostic potential of salivary interleukin‐17, RANKL, and OPG to differentiate between periodontal health and disease and discriminate stable and unstable periodontitis: A case‐control study
by: Marwa A. Abdullameer, et al.
Published: (2023-02-01)

Pneumococcal polyarticular septic arthritis after a single infusion of infliximab in a rheumatoid arthritis patient: a case report
by: Hayashi Masatoshi, et al.
Published: (2012-03-01)

Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence
by: Iannone F, et al.
Published: (2022-06-01)

Low infliximab serum trough levels and anti-infliximab antibodies are prevalent in rheumatoid arthritis patients treated with infliximab in daily clinical practice: results of an observational cohort study
by: van der Maas Aatke, et al.
Published: (2012-09-01)

Intraarticular Injection of Infliximab-Loaded Thermosensitive Hydrogel Alleviates Pain and Protects Cartilage in Rheumatoid Arthritis
by: Chen W, et al.
Published: (2020-12-01)